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Introduction
This paper provides some clinical suggestions regarding the
prescription of prophylactic headache treatment. The paper is
directed to primary care physicians and to algologists who do
not currently manage headache, and is based on the scientif-
ic evidence as summarized in the clinical guidelines elabo-
rated by the Italian Society for the Study of Headache [1, 2].
Indication for migraine prophylaxis:
what should be achieved?
The main goals of prophylactic treatment for migraine are to
decrease headache attack frequency, length and intensity, to
improve the efficacy of symptomatic drugs, to prevent the
frequent intake of analgesic and specific migraine drugs,
and to prevent the episodic headache from turning into
chronic headache [2, 3]. Therefore, clinical evaluation of the
patient, regarding the frequency, length and intensity of their
headache attacks, is preliminary to the evaluation of treat-
ment efficacy. In randomised clinical trials, a good answer
to prophylactic treatment is evaluated as a 50% responder
rate in 50% of the treated subjects [4, 5].
In everyday clinical practice, we often observe that in the
vast majority of patients migraine does not have a constant
trend and its time-related evolution depends on trigger fac-
tors often contingent and not foreseeable in the single sub-
ject. Only an adequately compiled headache diary concern-
ing the previous months can reveal eventual pain cycles and
help in deciding the preventive treatment start time and
length [6]. If this record is not available, we believe that
there is a risk of prescribing an ineffective drug too long or,
quite the opposite, of discontinuing the treatment before the
time necessary to observe the desired response to a poten-
tially effective drug.
Adequate therapeutic choices are not easy, even when
specific guidelines are available. First of all, it is necessary
to decide if, when and how to begin a prophylactic treat-
ment, but on this point there are no absolute indications [2].
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Some useful parameters to help in this choice are sum-
marised in Table 1. However, deciding not to treat is a ther-
apeutic choice and therefore it needs a rigorous scientific
approach. Each prescription decision requires the physician
to decide specific efficacy and safety goals at the treatment
beginning and to periodically re-evaluate the patient during
the therapy [7]. To monitor the patient, we can employ both
quantitative and qualitative indexes. Headache index, evalu-
ating migraine attack length and intensity or the number of
headache days, and the analgesic and specific migraine drug
intake are good quantitative indexes, while accompanying
symptoms, analgesic drug efficacy and patients’ quality of
life are examples of qualitative indexes [2, 8]. The treatment
results will obviously depend on the baseline characteristics
of the patients and of their migraine attacks and they are not
always those expected from the results of the main clinical
trials used to define the guidelines [9].
To relate the results of a treatment given in usual clinical
practice to those found in the scientific literature, guidelines
should clearly indicate the inclusion and exclusion criteria
applied to select the patients for whom the results are report-
ed [10]. Randomised clinical trials provide objectives and
systematic data on drug efficacy and safety, but they are
often inadequate to guide the therapeutic choices in the “real
world” outside the aseptic and ideal setting where they are
carried out [11, 12].
The choice of the “right” drug: some practical advice
In selecting a drug for prophylactic treatment, the most
important parameters to consider are the drug’s efficacy, tol-
erability and safety after prolonged assumption, known con-
traindications to the drug, possible pharmacological interac-
tions, and the acceptability by the patient [13]. Table 2
reports some elements that are still not clearly defined in the
scientific literature and thus not evidence-based regarding
migraine prophylactic treatment [14]. Monotherapy is
undoubtedly preferable, although in special cases, especial-
ly in patients resistant to more simple treatments, it possible
to use drug associations (Table 3) [2]. However, even if
commonly used, their efficacy and safety have not been ade-
quately demonstrated in well carried out and specifically
designed clinical trials [15]. 
A rational therapy requires not only an accurate diagno-
sis but also a good comprehension of the disease’s phys-
iopathology [16, 17]. Because migraine pathogenesis is not
well known, specific and resolutive therapies have not been
developed either. Drugs employed in prophylaxis are only
partially efficacious and the treatment result is often unsure
and unforeseeable [18]. 
From our everyday experience, we know that the pre-
ventive drug theoretically more efficacious in a patient may
not be the most appropriate drug for treating all the phases
of the patient’s migraine. Efficacy, safety, indications and
contraindications of a drug do not have absolute value, but
they depend on the migraine attack intensity and frequency
and on the patient’s characteristics. While a prophylactic
drug is ineffective, a drug of another therapeutic class or the
combination of drugs different could be [19].
Tables 4 and 5 present some recommendations useful,
respectively, for the physician and the patient regarding pro-
phylactic treatment [20, 21]. Not only is the choice of drug
problematic, but also the modality of a preventive treatment.
In fact, to obtain the patient’s compliance to the treatment
and to accelerate the therapeutic response it is theoretically
advantageous to rapidly increase the dose to the full dosage.
Table 1 Indications for prophylactic treatment of migraine
Migraine attack characteristics
At least 3 severe attacks in 30 days 
Attacks last more than 4 hours, or prolonged aura is present
Symptomatic medications are ineffective or the patient does not
tolerate their side effects
Patient’s quality of life is decreased by migraine in an unacceptable
way, even if symptomatic medications are effective and well
tolerated
Table 2 Evidence-based medicine and migraine prophylactic treat-
ment: some points not yet clearly defined
Predictive factors of effectiveness of the different drugs in specific
patient sub-categories
Strategies to start and to discontinue the treatment 
Minimal and maximal lengths of the pharmacological prophylaxis
Efficacy and inefficacy predictive factors for repetition of the same
drug
Indications for the sequential use of drugs of the same pharmaco-
logical class or of different classes
Table 3 Drug combinations used in migraine prophylaxis
Possible combinations
Antidepressants and beta-blockers
Antidepressants and calcium-channel blockers
Antidepressants and valproic acid
Beta-blockers and flunarizine
Combinations used with caution
Beta-blockers and verapamil
On the other hand, in this way we increase the risk that the
patient develops side effects and discontinues the treatment
before experiencing its benefit [22]. Thus, slow dose escala-
tion is generally recommended (this does not apply, for
instance, to flunarizine). It is generally agreed, instead, that
the treatment has to be interrupted slowly, tapering the
dosage to avoid rebound symptoms, and that the dosage
should rapidly be re-increased if migraine immediately
worsens. However, this event is infrequent, because most
drugs employed in migraine prophylaxis have a carryover
effect that continues after treatment interruption [23].
Comorbidities and drug-drug interactions
Medical and psychiatric co-morbidities significantly influence
the choice of prophylactic drug. The coexistence of a second
illness imposes the physician to exclude those medications
that are contraindicated as, for example, beta-blockers in asth-
matic patients [24]. In Table 6, we report the most relevant
contraindications and indications. In patients with psychiatric
co-morbidity, the prescription of one drug to treat both
pathologies could be a suitable solution. However, drugs with
double indications are few, and the employment of two differ-
ent specific drugs has the advantage of allowing the indepen-
dent modulation of the doses on the basis of the desired effect
[25]. Finally, it is important to remember that drug combina-
tions are always a possible cause of pharmacokinetic and
pharmacodynamic interactions (partially avoidable selecting
the drugs to associate on the basis of the more widely known
contraindications), and these treatments must be constantly
monitored to speedily recognise eventual interactions [16].
Drugs can interact at many levels and cause addictive
toxicity that is specific and often not foreseeable based on
the knowledge of the single agents. It is an ingenuity to pre-
sume that there is no interaction between two drugs only
because no previous toxicity data have been reported [26]. It
is especially relevant to remember the possibility of phar-
macological interactions even between compounds used for
acute and prophylactic treatment of headache. Sumatriptan
and rizatriptan are metabolised selectively by the
monoamine oxidases (MAO) so that they may interact only
with MAO inhibitors, rarely employed in Italy [27, 28].
Other triptans are metabolised partially or totally by the
cytochrome P450 system, so that inhibitors or inducers of
15
Table 4 Our main recommendations for physicians who prescribe a migraine prophylaxis 
Chose the drug considering the eventual medical or psychiatric co-morbidity (there is no well established order to follow in prescribing
the different prophylactic drug classes)
Prefer monotherapy in order to more easily evaluate both efficacy and side effects (especially the causal relationship) of the employed drug
Continue therapy for the time required to verify drug efficacy (encourage patients to follow the treatment even if the benefit is not imme-
diate) and then prolong it for a variable time on the basis of the drug used and the patient’s characteristics
Obtain patient compliance by explaining frequent drug side effects and by using long-acting formulations (reducing the number of daily
doses can improve patient compliance)
Explain to the patient that an excessive use of analgesic and specific migraine drugs can reduce the efficacy of prophylactic treatment
Remember that the efficacy of prophylactic treatment decreases after some months and that further prophylatic cycles give hardly the same
results as the first
Evaluate the usefulness of reducing the dosage to the minimal effective dosage or of slowly tapering it when the desired benefit has been
obtained
Verify periodically the efficacy of therapy and the patient’s compliance by monitoring the headache diary
Re-evaluate the diagnosis in case of resistance to treatments with drugs of different pharmacological categories, if the attack frequency is
always elevated, when the patient excessively uses symptomatic drugs or if the migraine characteristics change
Table 5 Explanations that can be given to a patient who has to begin migraine prophylaxis
The aims of prophylactic treatment are to decrease the headache attack frequency, length and intensity, to improve the efficacy of symp-
tomatic drugs, to reduce their need, and to prevent the episodic headache from turning into a chronic headache
Patient co-operation is indispensable, and the therapy must be followed according to the physician’s prescription, even for many months
Sometimes side effects appear before the therapeutic effect, which usually begins after several weeks of treatment (sometimes even after
2–3 weeks)
Often side effects are only transient and disappear within the first few days of treatment
Usually the prophylactic treatment does not completely eliminate migraine attacks: often it decreases the frequency, but not the intensity
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the specific metabolising isoforms could cause some phar-
macological interactions. However, the main reported inter-
action between drugs assumed for symptomatic treatment
and prophylactic drugs is that between propranolol and
zolmitritpan. The drug-drug interaction is, however, not
clinically significant when patients use a dose of 2.5 mg, as
usually done in Italy [29]. From a pharmacodynamic point
of view, the co-assumption of a triptan and a serotoninergic
drug, like most antidepressant drugs used in headache pro-
phylaxis, increases the risk of developing a serotoninergic
syndrome [30]. So, the drugs to begin a prophylactic treat-
ment has to be adequately chosen even considering the risk
of pharmacodynamic and pharmacokinetic interactions with
drug usually assumed for symptomatic headache treatment.
Table 6 Preventive management of migraine: main relative contraindications and indications for the  choice  of drugs in comorbid condi-
tions. Only drugs available on the Italian market with levels of evidence A and B and known clinical effectiveness as reported in the guide-
lines of the Italian Society for the Study of Headache [1, 2] are listed
Drug class Contraindications Indications
Beta blockersa Congestive heart failure, bradycardia, arterial Angina pectoris, hypertension, tachycardia, anxiety,
hypotension, peripheral vascular diseases, asthenia, panic attack, essential tremor (proporanolol)
depression, dizziness, asthma, emphysema,
insulin-dependent diabetes, pregnancy, lactation
Calcium-channel blockers
Verapamil A-V block, hypotension, constipation, bradycardia Asthma, hypertension, tachycardia,
stroke, prolonged aura
Nimodipine Abdominal discomfort, gastroesophageal reflux, Asthma, hypertension, bradycardia
hypotension, tachycardia
Flunarizine, Asthenia, depression, obesity, parkinsonisms, Asthma
cinnarizine pregnancy, lactation
Antidepressants
Amitriptyline Drowsiness, obesity, constipation, urinary retention, Panic disorders, depression,
bradycardia, QT prolungation, mania anxiey disorders, tension-type headache,
depression, Horton’s syndrome
Fluoxetine Asthenia, insomnia, dyspepsia, tremors Same as for amitriptyline
Pizotifen Asthenia, obesity, pregnancy, asthenia, Same as for amitriptyline
glaucoma, prostatic hypertrophy
Antiepileptics
Valproic acid Liver disease, hemorragic diatheses, Prolonged or atypical migraine
asthenia, tremors, obesity, pregnancy
Gabapentin Asthenia, dizziness, pregnancy, lactation Neuropathic pain
a Atenolol, propanolol, metoprolol and nadolol
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